Premium
Anixa Biosciences Inc (ANIX)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is devel... Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. It is developing the CchekTM platform, a series of inexpensive non-invasive blood tests for early detection of solid tumours which is based on the body's immune response to the presence of a malignancy. The company is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs that genetically engineer patient's own immune cells to fight cancer. Show more
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset PR Newswire SAN JOSE, Calif., Nov. 22, 2024 SAN JOSE, Calif., Nov. 22, 2024 /PRNewswire/ -- Anixa...
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial PR Newswire SAN JOSE, Calif., Nov. 18, 2024 Third cohort dose is one million CAR positive cells; ten...
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting PR...
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting PR...
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 PR Newswire SAN JOSE, Calif., Oct. 31, 2024 SAN JOSE, Calif., Oct. 31, 2024 /PRNewswire/...
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting PR Newswire SAN...
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial PR Newswire SAN JOSE, Calif., Oct. 15, 2024 Patient showed clinical activity after initial...
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development PR Newswire SAN JOSE, Calif., Oct. 7, 2024 SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.05 | -1.48367952522 | 3.37 | 3.46 | 3.14 | 67290 | 3.26013739 | CS |
| 4 | -0.13 | -3.76811594203 | 3.45 | 4.2 | 3.02 | 150714 | 3.25168931 | CS |
| 12 | 0.15 | 4.73186119874 | 3.17 | 4.2 | 2.93 | 96552 | 3.34476983 | CS |
| 26 | 0.89 | 36.6255144033 | 2.43 | 4.2 | 2.16 | 97917 | 3.12350818 | CS |
| 52 | 0.02 | 0.606060606061 | 3.3 | 5.13 | 2.16 | 131842 | 3.55028285 | CS |
| 156 | 0.07 | 2.15384615385 | 3.25 | 6.45 | 2.16 | 97354 | 3.68621599 | CS |
| 260 | -0.4 | -10.752688172 | 3.72 | 8.09 | 1.33 | 193905 | 3.74567555 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
